Skip to content

Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients

Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03413293
Enrollment
20
Registered
2018-01-29
Start date
2018-06-30
Completion date
2019-08-31
Last updated
2018-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nosocomial Infection

Brief summary

Hospital acquired chest Infections are common complications in hospitalized cirrhotic patients. Infectious complications are the most common cause of mortality in cirrhotic patients with bronchopneumonia early antibiotic treatment at the base of culture and sensitivity is an optimal therapeutic approach in cirrhotics with nosocomial pneumonia Intensive care unit acquired pneumonia is the leading infection in critically ill patients and a major cause of morbidity and mortality despite recent major advances in antimicrobial therapy, supportive care, and the use of a broad range of preventive measures

Detailed description

Aim of the work 1. To estimate the frequency and risk factors of nosocomial chest infections in cirrhotic patients . 2. To determine the causative pathogens of nosocomial chest infections in patients with cirrhosis including fungal infections in order to establish our local empirical antimicrobial protocol. 3. To define the impact of nosocomial chest infections on survival of our patients. 4. To develop an effective and continuous surveillance program and infection control measures to reduce the burden of these infections as well as morbidity , mortality , hospital stay ,hospital cost and to achieve quality of care . 5. To motivate pharmaceutical companies to create a new umbrella coverage of antimicrobials through the ongoing knowledge of the changes in microbial resistance pattern inside hospitals

Interventions

DIAGNOSTIC_TESTDiagnosis of bacterial infections

Cultures

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All cirrhotic patients , decompensated , child pug score B or C ,may have Hepatocellular carcinoma , other comorbidities may present as (Diabetius mellitus , Hypertension , Heart disease and renal impairment ) , both sex and with clinical suspicion of chest infections acquired after 48 hours of admission

Exclusion criteria

* Patients have any chronic chest disease * Patients have severe immunosuppression (neutropenia after chemotherapy or hematopoietic transplant, drug-induced immunosuppression in solid-organ transplant or cytotoxic therapy, and HIV-related disorders.

Design outcomes

Primary

MeasureTime frameDescription
Frequency of nosocomial infection in patients with liver cirrhosisbaselinenosocomial infection is one of predictors of bad outcome in liver cirrhosis

Contacts

Primary ContactNariman zaghluol bakhiet, postgraduate
narimandoctor@yahoo.com01005546130

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026